Angela T H Kwan, Ziji Guo, Felicia Ceban, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Taeho Greg Rhee, Roger Ho, Joshua D Di Vincenzo, Sebastian Badulescu, Shakila Meshkat, Bing Cao, Joshua D Rosenblat, Giacomo d'Andrea, Donovan A Dev, Lee Phan, Mehala Subramaniapillai, Roger S McIntyre
INTRODUCTION: To date, there are no therapeutics that have gained regulatory approval by the United States Food and Drug Administration (FDA) for the treatment of post-COVID-19 condition (PCC), a debilitating condition characterized by cognitive impairment and mood symptoms. Additionally, persistent inflammation, metabolic dysfunction, and risks associated with an elevated body mass index (BMI) have been observed. Herein, we aimed to assess the efficacy of vortioxetine in improving depressive symptoms among individuals with PCC, as modulated by inflammation, metabolic dysfunction, and BMI...
March 23, 2024: Advances in Therapy